Teach on Udemy

Turn what you know into an opportunity and reach millions around the world.

Learn More

Your cart is empty.

Keep shopping

Certificate Course in Pharmaceutical Market Access

Name: Certificate Course in Pharmaceutical Market Access
Rating: 4.2 (299 reviews)

HTA, pricing, HEOR, RWE, US payers and the EU Joint Clinical Assessment - with case studies, role plays & workbooks 2026

Created byAccess Health Academy

Last updated 10/2026

English

English [Auto],

What you'll learn

Master key market access strategies to launch successful pharmaceutical products globally
Gain expertise in health economics, pricing strategies, and regulatory frameworks, essential for pharma careers
Learn to navigate the payer ecosystem for optimal drug reimbursement and broader patient access
Understand the impact of health technology assessments (HTAs) and real-world evidence in drug approval
Acquire skills in stakeholder engagement and effective communication to influence healthcare decisions
Calculate a gross-to-net stack and a Medicare negotiation timeline yourself, in workbooks where every formula is live
Work six case studies with real numbers, each with a debrief showing the full arithmetic
Discover the role of patient advocacy in improving access to medications and shaping healthcare policies
Dive into global market access considerations, understanding diverse healthcare systems and policies
Spot the classic errors before a reviewer does: dominated comparators, mapped utilities, immortal time bias, cost-effective but unaffordable
Apply the EU HTA Regulation in practice: joint clinical assessment scope, submission, PICO consolidation and joint scientific consultations
Navigate the US system: pharmacy benefit managers, formulary tiers, Medicare Part B and D, Medicaid best price, 340B and the Inflation Reduction Act
Rehearse five payer conversations with an AI counterpart that pushes back the way the real one does

Course content

25 sections • 204 lectures • 32h 49m total length

Why Market Access1:43
What no course teaches — and why I publish it every week2:15

1.1 Constructing a decision-ready access strategy5:08
1.2 From regulatory approval to effective patient access5:31
1.3 Stakeholders, incentives and decision rights5:27
1.4 Patient journeys and quantitative access funnels5:18
1.5 Diagnosing and prioritising access barriers5:30
1.6 Translating clinical evidence into an access value proposition5:12
1.7 Population segmentation and strategic prioritisation5:20
1.8 Stress-testing and governing the access strategy5:34
1.9 Applied access blueprint: an integrated worked case5:10
Professional toolkit | Core 1: Access Strategy and Patient Journey

Download and unzip Core_01_Professional_Toolkit.zip from this lecture's resources. Start with READ_ME, then complete the three editable Word templates and the companion Excel scenarios.

Bring in: Start a project record with product, indication, population, market, comparator and planning period. Use a fictional product or non-confidential information.

Carry forward: Send the target population, comparator questions and three decision-changing barriers to Core 2. Preserve patient-flow definitions for the Core 4 budget model.

Keep one project ID and version history across the course. The examples are fictional. For the Final Assignment, use its supplied MA1001 case facts and submission instructions.
Core 1 Quiz: Market Access Strategy & the Patient Journey
Core 1: Why Are Patients Still Not Being Treated?

2.1 Early access strategy across the development lifecycle5:43
2.2 Target product profiles and target access profiles5:53
2.3 Anticipating PICOs and choosing comparators5:53
2.4 Endpoints, estimands and patient-relevant evidence6:03
2.5 Integrated evidence planning and global–local reuse6:03
2.6 Prioritising evidence through decision sensitivity and value of information6:09
2.7 Scientific advice and joint consultation6:02
2.8 Evidence-plan debrief: uncertainty, decisions and change control5:57
2.9 Applied integrated evidence plan: a worked development case6:41
Professional toolkit | Core 2: Target Access Profile and Evidence Planning

Download and unzip Core_02_Professional_Toolkit.zip from this lecture's resources. Start with READ_ME, then complete the three editable Word templates.

Bring in: Bring T01-01, the comparator questions, barrier IDs and the patient cohort definition.

Carry forward: Pass prioritised PICOs, evidence IDs and claim limitations to Core 3. Send the economic uncertainties to Core 4 and study questions to Core 5.

Keep one project ID and version history across the course. The examples are fictional. For the Final Assignment, use its supplied MA1001 case facts and submission instructions.
Core 2 Quiz: Early Strategy & Integrated Evidence Planning
Core 2: Protocol Lock — Protecting Future Access

3.1 HTA as comparative evidence assessment and decision support5:41
3.2 EU joint clinical assessment: legal scope and operating logic5:52
3.3 Connecting JCA to national HTA and reimbursement5:53
3.4 JCA scoping and the management of multiple PICOs5:48
3.5 Building an assessment-ready clinical evidence dossier5:46
3.6 Certainty, clinical relevance and subgroup interpretation6:00
3.7 Indirect comparisons: assumptions, methods and defensible claims6:05
3.8 Defending clinical conclusions across joint and national review5:56
3.9 Applied JCA evidence-gap analysis6:04
Professional toolkit | Core 3: HTA Evidence and Claim Control

Download and unzip Core_03_Professional_Toolkit.zip from this lecture's resources. Start with READ_ME, then complete the three editable Word templates.

Bring in: Bring the target access profile, PICO IDs, comparator rationale and funded evidence plan from Core 2.

Carry forward: Pass supported effect estimates, uncertainty and permitted claims to Core 4. Carry national gaps to Core 7 and claim IDs to Core 10.

Keep one project ID and version history across the course. The examples are fictional. For the Final Assignment, use its supplied MA1001 case facts and submission instructions.
Core 3 Quiz: HTA & EU Joint Clinical Assessment
Core 3: Defend the JCA Evidence Package

4.1 Economic evaluation: opportunity cost and the decision rule6:02
4.2 Measuring health outcomes: utilities, QALYs and their limitations6:15
4.3 Model quality assurance and transparent reporting5:59
4.4 Evidence inputs and survival extrapolation6:03
4.5 Model structures: decision trees, state-transition models and simulation6:17
4.6 Economic evidence debrief: defending the decision, not the model6:10
4.7 Uncertainty analysis and the interpretation of economic results6:29
4.8 Budget impact analysis: populations, displacement and cash flow5:59
4.9 Applied economic case: integrating value, price and affordability6:47
Professional toolkit | Core 4: Economic Value and Budget Impact

Download and unzip Core_04_Professional_Toolkit.zip from this lecture's resources. Start with READ_ME, then complete the three editable Word templates and the companion Excel scenarios.

Bring in: Bring the patient-flow definitions, clinical effect estimates, comparator relevance and evidence uncertainties from Cores 1 to 3.

Carry forward: Send the economic conditions and price sensitivities to Core 6. Feed data gaps to Core 5 and local model requirements to Core 7.

Keep one project ID and version history across the course. The examples are fictional. For the Final Assignment, use its supplied MA1001 case facts and submission instructions.
Core 4 Quiz: HEOR, Cost-Effectiveness & Budget Impact
Core 4 Lab: Audit Value and Affordability

5.1 Real-world evidence: matching the evidence to the decision5:48
5.2 Data fitness: provenance, measurement and linkage5:56
5.3 External controls and evidence triangulation5:56
5.4 Confounding adjustment and the limits of statistical sophistication5:41
5.5 Target trial emulation and the design of causal questions5:45
5.6 Patient experience, resource use and implementation evidence5:53
5.7 Critical appraisal and responsible use of RWE5:48
5.8 Lifecycle evidence systems: registries, reassessment and learning5:52
5.9 Applied RWE case: from an attractive dataset to a defensible study5:40
Professional toolkit | Core 5: RWE Study Design and Data Fitness

Download and unzip Core_05_Professional_Toolkit.zip from this lecture's resources. Start with READ_ME, then complete the three editable Word templates.

Bring in: Bring the decision-sensitive gaps from Cores 2 to 4. Specify whether the evidence will change a claim, model input or implementation action.

Carry forward: Pass qualified findings to the Core 3 claim register and updated inputs to Core 4. Carry registry and reassessment commitments to Cores 9 and 10.

Keep one project ID and version history across the course. The examples are fictional. For the Final Assignment, use its supplied MA1001 case facts and submission instructions.
Core 5 Quiz: Real-World Evidence Across the Product Lifecycle
Core 5 Lab: Rescue an RWE Study Before It Misleads

6.1 From Value Evidence to a Price Corridor5:50
6.2 Gross-to-Net: Build a Transparent Price Waterfall5:40
6.3 External Reference Pricing and Cross-Market Spillovers5:51
6.4 Launch Sequencing Under Evidence and Price Constraints5:56
6.5 Financial Agreements: Discounts, Caps and Price-Volume5:51
6.6 Outcomes-Based Agreements: Endpoint, Data and Settlement5:48
6.7 US International Price Benchmarking: Live Policy Watch5:56
6.8 Lifecycle Pricing, Competition and Biosimilars5:52
6.9 Case Lab: Where to Launch First6:35
Professional toolkit | Core 6: Pricing Contracting and Launch Sequence

Download and unzip Core_06_Professional_Toolkit.zip from this lecture's resources. Start with READ_ME, then complete the three editable Word templates and the companion Excel scenarios.

Bring in: Bring qualified claims, value and budget results, evidence costs and implementation constraints from Cores 1 to 5.

Carry forward: Send the conditional commercial package to country planning in Core 7, benefit-specific US analysis in Core 8 and execution in Cores 9 and 10.

Keep one project ID and version history across the course. The examples are fictional. For the Final Assignment, use its supplied MA1001 case facts and submission instructions.
Core 6 Quiz: Pricing, Contracting & Global Launch Sequencing
Core 6: Negotiate Access Under a Hard Budget

7.1 Comparing reimbursement systems without creating false equivalence6:00
7.2 Germany: added benefit, comparator discipline and negotiation6:19
7.3 France: clinical benefit, improvement and price formation6:00
7.4 United Kingdom: evidence synthesis, economic appraisal and implementation6:23
7.5 Italy: national negotiation, evidence and regional execution6:15
7.6 Spain: funding, price and decentralised implementation6:24
7.7 Nordic and selected global routes: functional comparison6:35
7.8 Country strategy debrief: separating requirement, custom and choice5:57
7.9 Applied country planning: the global core and local decision gaps6:16
Professional toolkit | Core 7: Country Reimbursement and Local Adaptation

Download and unzip Core_07_Professional_Toolkit.zip from this lecture's resources. Start with READ_ME, then complete the three editable Word templates.

Bring in: Bring the Core 3 clinical file, Core 4 model scope and Core 6 commercial conditions. Keep a common product and indication version.

Carry forward: Return local evidence gaps to Cores 2 and 3. Send verified national and regional dependencies to the Core 10 launch plan.

Keep one project ID and version history across the course. The examples are fictional. For the Final Assignment, use its supplied MA1001 case facts and submission instructions.
Core 7 Quiz: European & Global Reimbursement Pathways
Core 7 Lab: Build a Country Access Plan That Can Execute

8.1 US access system: coverage, payment and patient affordability7:12
8.2 The pharmacy benefit: formularies, benefit design and specialty distribution6:52
8.3 Formulary decisions and utilisation management: evaluating access quality6:39
8.4 The medical benefit: buy-and-bill, coding and provider economics6:53
8.5 US gross-to-net economics and channel-sensitive forecasting6:57
8.6 Medicare reform: negotiated prices, Part D redesign & strategic implications7:23
8.7 US access debrief: claims, metrics and an executable account strategy7:15
8.8 US payer evidence: building an AMCP-style decision dossier7:00
8.9 Applied US access case: integrating benefit, economics and patient pathways7:44
Professional toolkit | Core 8: US Payer Account and Patient Access

Download and unzip Core_08_Professional_Toolkit.zip from this lecture's resources. Start with READ_ME, then complete the three editable Word templates and the companion Excel scenarios.

Bring in: Bring the value claim cards and economic assumptions. Treat US benefit and channel definitions as account-specific inputs to verify.

Carry forward: Send benefit-specific evidence gaps to Core 2, data questions to Core 5 and accountable access actions to Core 10.

Keep one project ID and version history across the course. The examples are fictional. For the Final Assignment, use its supplied MA1001 case facts and submission instructions.
Core 8 Quiz: US Market Access, Payers & Medicare Reform
Core 8: Win Useful Access, Not a Formulary Badge

9.1 Early access: distinguish treatment routes, trials and reimbursement6:36
9.2 National early-access routes: compare responsibilities, funding & transition7:05
9.3 Ethics and evidence in early access: learn without overstating causality6:40
9.4 Designing an early-access operating model: supply, safety, cost & continuity7:00
9.5 Complex therapies: why evidence and access problems differ structurally6:38
9.6 Economic evaluation and payment design for one-time therapies7:10
9.7 Treatment capacity, centres of excellence and equitable implementation6:36
9.8 Complex-therapy debrief: responsible access & credible lifecycle commitments7:08
9.9 Applied complex-therapy case: evidence, funding & delivery under uncertainty7:44
Professional toolkit | Core 9: Early Access and Complex Therapy Delivery

Download and unzip Core_09_Professional_Toolkit.zip from this lecture's resources. Start with READ_ME, then complete the three editable Word templates and the companion Excel scenarios.

Bring in: Bring the pathway, evidence plan, country verification and conditional commercial terms. Distinguish routine reimbursement from any interim route.

Carry forward: Pass verified centre capacity, funding gaps, continuity commitments and reassessment triggers to the Core 10 execution plan.

Keep one project ID and version history across the course. The examples are fictional. For the Final Assignment, use its supplied MA1001 case facts and submission instructions.
Core 9 Quiz: Early Access Programs & Complex Therapies
Core 9: Fund the Therapy — and Deliver the Treatment

Requirements

No specific prerequisites are required for this transformative journey into Market Access. Whether you're new to the pharmaceutical industry or looking to expand your expertise, this course is crafted to welcome anyone with a passion for making a difference in healthcare. Embrace the opportunity to propel your career into a future where your impact is immeasurable. Let your curiosity and desire to contribute to medical innovation be your guide.
No prior experience in market access, health economics or the pharmaceutical industry is required. Everything is built from first principles.
A spreadsheet application for the workbooks. No modelling software, no statistics package and no coding.
English at a professional reading level. All lectures, templates, case studies and quizzes are in English.

Description

Twenty-one hours of teaching, six worked case studies, five AI role plays, fifteen quizzes with 197 questions, a 40-question final exam and 88 downloadable resources. Updated through OCTOBER 2026.

Market access decides whether a medicine that works ever reaches a patient. This course teaches the whole discipline - what to prove and against which comparator, what a product is worth, what price to ask for and to accept, which patients to fund first, and where to launch - across both the European and the American systems.

What is inside

Foundations. What market access actually is, the access value chain, five payer archetypes, and why list price, net price, payer cost and patient cost are four different numbers.
The United States. Pharmacy benefit managers, rebates, formulary tiers and prior authorisation, Medicare Part B and Part D, Medicaid best price, 340B, and the Inflation Reduction Act as it stands in 2026.
Health technology assessment and health economics. QALYs, ICERs, budget impact, systematic review and meta-analysis, patient-reported outcomes, indirect comparisons and critical appraisal.
Europe and the EU HTA Regulation. Joint clinical assessment as it has actually run since January 2025: scope, submission, the HTA IT platform, PICO consolidation and joint scientific consultations.
Pricing, real-world evidence, early access, negotiation, regulatory affairs, biosimilars and generics, plus where artificial intelligence genuinely changes this work and where it does not.

What you do, not just watch

Six case studies with real numbers. Choose a phase 3 comparator four weeks before the protocol locks. Decide between two offers from a benefit manager covering 42 million lives. Find three errors in a cost-effectiveness model before the assessment body does. Sequence five launches under international reference pricing. Prioritise seven PICO comparisons when you have data for one. Take apart a real-world study claiming a 34 per cent mortality reduction. Each has a briefing, working space and a debrief with the full arithmetic.
Five AI role plays. Spoken practice against a counterpart who pushes back the way the real one does: a US benefit manager, a German assessor, a national payer refusing on budget impact, your own commercial director, and a hospital committee with a fixed budget in July.
Live workbooks. A US gross-to-net and Medicare negotiation calculator, an early access route comparator, and two EU HTA planning tools. Every formula works, so you change an assumption and watch the answer move.
A decoder of 130 terms, in Word and PDF, with three columns: the acronym, what it stands for, and what it actually means.

Current as of 2026. Positions verified against primary sources: the first joint clinical assessment report adopted in April 2026, the first negotiated Medicare prices in force since January 2026, the UK payment rate for 2026, and the reformed early access schemes in France, Germany, Italy, the United Kingdom and the United States.

How to use it. Chapter 1 gives you the whole field in twelve minutes and three routes through the course: an interview in two weeks, learning it properly, or one specific topic. You do not have to take sixteen chapters in order, and you should not.

Chapters 2 and 3 are written guides with downloadable tools rather than video. Video runs from chapter 4 onwards.

Embark on an enlightening adventure into the pivotal world of Pharmaceutical Market Access, a crucial domain pivotal to the advancement of healthcare and patient well-being. This detailed and expansive course delves deep into the core aspects of Health Technology Assessment (HTA), Real World Evidence (RWE), Health Economics and Outcomes Research (HEOR), Patient Access, Innovation, and Early Access, uncovering the layers and complexities involved in bringing revolutionary medical treatments from conception to the hands of those in need.

With a curriculum designed for both seasoned professionals and newcomers eager to leave their mark in the pharmaceutical sector, this course offers a rare glimpse into the strategic and operational facets of market access. You will be equipped with the knowledge to not only understand but also influence the multifaceted decision-making processes that determine the success and reach of new healthcare solutions.

Through a blend of theoretical knowledge and practical insights, gain the expertise to navigate the regulatory landscapes, understand the economic impact, and advocate for patient access to essential medications. Learn from industry experts and case studies that bring to life the challenges and triumphs of ensuring that groundbreaking therapies are available, affordable, and attainable for patients around the globe.

This course is your gateway to becoming a key player in the pharmaceutical industry, where you'll be empowered to drive innovation, influence healthcare policy, and contribute to the shaping of future medical breakthroughs. By enrolling, you're not just signing up for a course; you're stepping into a community dedicated to making a lasting impact on global health. Your journey towards mastering Pharmaceutical Market Access starts here. Seize this opportunity to be at the forefront of healthcare evolution, and play a part in delivering hope and healing to millions worldwide.

Who this course is for:

This course opens doors to one of the most rewarding and high-demand careers in the pharmaceutical industry: Market Access. If you're intrigued by the crucial role of bringing medical innovations to the patients who need them, this course is designed for you. Tailored for both newcomers eager to learn how drugs are brought to market and professionals aiming to advance their careers within pharmaceutical companies, life sciences consulting, or HEOR (Health Economics and Outcomes Research) analysis. Take the first step towards a career where your work is not only well-compensated but also makes a meaningful difference in people’s lives. Join us and become an expert in Market Access, a field with boundless growth and opportunities!
Professionals moving into market access, HEOR or pricing from clinical, medical affairs, regulatory, sales or consulting roles
Market access teams who need the 2026 position on the EU Joint Clinical Assessment and on Medicare price negotiation
Consultants and analysts who must read and challenge a payer dossier or an economic model rather than build one
Anyone preparing for a market access interview who needs to be conversant across HTA, pricing, RWE and both the US and European systems

Certificate Course in Pharmaceutical Market Access

What you'll learn

Explore related topics

Course content

Welcome to Pharmaceutical Market Access2 lectures • 4min

CORE 1 — Market Access Strategy & the Patient Journey10 lectures • 48min

CORE 2 — Early Strategy & Integrated Evidence Planning -10 lectures • 54min

CORE 3 — HTA & EU Joint Clinical Assessment in Practice10 lectures • 53min

CORE 4 — HEOR, Cost-Effectiveness & Budget Impact9 lectures • 56min

CORE 5 — RWE & Evidence Across the Product Lifecycle9 lectures • 52min

CORE 6 — Pricing, Contracting & Global Launch Sequencing10 lectures • 53min

CORE 7 — European & Global Reimbursement Pathways9 lectures • 56min

CORE 8 — US Market Access: Payers, Benefits & Medicare Reform10 lectures • 1hr 4min

CORE 9 — Early Access Programs & Complex Therapies10 lectures • 1hr 3min

Requirements

Description

Who this course is for: